J. Wigginton

发表

Nivolumab plus ipilimumab in advanced melanoma.

C. Horak, J. Wolchok, M. Sznol, 2013, The New England journal of medicine.

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

David C. Smith, J. Taube, M. Atkins, 2012, The New England journal of medicine.

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

C. Drake, P. Hwu, A. Korman, 2012, The New England journal of medicine.

A phase 1b/2, open label, dose-escalation study of margetuximab (M) in combination with pembrolizumab (P) in patients with relapsed/refractory advanced HER2+ gastroesophageal (GEJ) junction or gastric (G) cancer.

E. Schmidt, P. Philip, J. Wigginton, 2017 .

Emerging concepts in biomarker discovery; The US-Japan workshop on immunological molecular markers in oncology

E. Petricoin, L. Liotta, F. Marincola, 2009, Journal of Translational Medicine.

Immunologic and Therapeutic Synergy of IL-27 and IL-2: Enhancement of T Cell Sensitization, Tumor-Specific CTL Reactivity and Complete Regression of Disseminated Neuroblastoma Metastases in the Liver and Bone Marrow1

G. Trinchieri, R. Kastelein, J. Wigginton, 2009, The Journal of Immunology.

Bone Marrow Neuroblastoma Metastases in the Liver and and Complete Regression of Disseminated Sensitization , Tumor-Specific CTL Reactivity IL-27 and IL-2 : Enhancement of T Cell Immunologic and Therapeutic Synergy of and

G. Trinchieri, R. Kastelein, J. Wigginton, 2009 .

Intradermal delivery of IL-12 naked DNA induces systemic NK cell activation and Th1 response in vivo that is independent of endogenous IL-12 production.

J. Wigginton, R. Fenton, R. Wiltrout, 1999, Journal of immunology.

Regulation of local host-mediated anti-tumor mechanisms by cytokines: direct and indirect effects on leukocyte recruitment and angiogenesis.

J. Wigginton, J. Ortaldo, R. Wiltrout, 1997, The American journal of pathology.

Synergistic Engagement of an Ineffective Endogenous Anti-Tumor Immune Response and Induction of IFN-γ and Fas-Ligand-Dependent Tumor Eradication by Combined Administration of IL-18 and IL-21

W. Alvord, J. Wigginton, T. Back, 2002, The Journal of Immunology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Anti‐tumour synergy of cytotoxic chemotherapy and anti‐CD40 plus CpG‐ODN immunotherapy through repolarization of tumour‐associated macrophages

J. Wigginton, A. Rakhmilevich, P. Sondel, 2011, Immunology.

A phase I study to evaluate safety and antitumor activity of biweekly BMS-936558 (Anti-PD-1, MDX-1106/ONO-4538) in patients with RCC and other advanced refractory malignancies.

J. Sosman, C. Drake, D. Smith, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Infant Botulism

J. Wigginton, Peter Thill, 1993, Clinical pediatrics.

Survival and long-term follow-up of the phase I trial of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC).

L. Sequist, S. Gettinger, J. Wigginton, 2013 .

Clinical Activity and Safety of Anti-Programmed Death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in Patients (PTS) with Advanced Non-Small Cell Lung Cancer (NSCLC)

L. Sequist, S. Gettinger, J. Wigginton, 2012 .

Regulation of ITAM-positive receptors: role of IL-12 and IL-18.

N. Bhat, J. Wigginton, H. Young, 2006, Blood.

Apoptotic Potential of Cytokine Therapy for Proteasome Inhibition to Maximize the

S. Lockett, J. Wigginton, J. Stauffer, 2013 .

Proteasome Inhibition to Maximize the Apoptotic Potential of Cytokine Therapy for Murine Neuroblastoma Tumors1

S. Lockett, J. Wigginton, T. Sayers, 2006, The Journal of Immunology.

Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors.

S. Lockett, J. Wigginton, T. Sayers, 2004, Journal of immunology.

IL-12/IL-2 combination cytokine therapy for solid tumours: translation from bench to bedside

J. Wigginton, R. Wiltrout, 2002, Expert opinion on biological therapy.

Combination immunotherapy: a road map The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

J. Wolchok, F. Hodi, P. Ott, 2017 .

Synergistic Anti-Tumor Responses After Administration of Agonistic Antibodies to CD40 and IL-2: Coordination of Dendritic and CD8+ Cell Responses 1

J. Wigginton, T. Sayers, T. Back, 2003, The Journal of Immunology.

Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19

F. Marincola, P. Ascierto, M. Atkins, 2020, Journal for ImmunoTherapy of Cancer.

Molecular mechanisms of immune-mediated lysis of murine renal cancer: differential contributions of perforin-dependent versus Fas-mediated pathways in lysis by NK and T cells.

J. Wigginton, T. Sayers, A. Brooks, 1998, Journal of immunology.

TFas-Mediated Pathways in Lysis by NK and Contributions of Perforin-Dependent Versus Lysis of Murine Renal Cancer : Differential Molecular Mechanisms of Immune-Mediated

J. Wigginton, T. Sayers, A. Brooks, 1998 .

Clinical activity and safety of anti-PD1 (BMS-936558, MDX-1106) in patients with advanced non-small-cell lung cancer (NSCLC).

L. Sequist, S. Gettinger, J. Wigginton, 2012 .

A phase 1 study of enoblituzumab in combination with pembrolizumab in patients with advanced B7-H3-expressing cancers.

A. Tolcher, P. Moore, N. Rizvi, 2016 .

Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3

K. Flaherty, A. Ribas, P. Moore, 2015, Journal of Immunotherapy for Cancer.

Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma.

J. Franco, J. Wigginton, T. Back, 1996, Journal of the National Cancer Institute.

IFN- γ and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy Systemic administration of IL-12 and intermittent doses of IL-2

K. Nagashima, J. Wigginton, Jong-Wook Park, 2022 .

Endogenous IL-12 Production Response In Vivo That Is Independent of Th1 Induces Systemic NK Cell Activation and Intradermal Delivery of IL-12 Naked DNA

J. Wigginton, R. Fenton, R. Wiltrout, 1999 .

Antitumor activity of interleukin 12 in preclinical models

J. Wigginton, L. Luistro, R. Wiltrout, 1996, Cancer Chemotherapy and Pharmacology.

Primary Hepatocytes from Mice Treated with IL-2/IL-12 Produce T Cell Chemoattractant Activity that Is Dependent on Monokine Induced by IFN-γ (Mig) and Chemokine Responsive to γ-2 (Crg-2)1

J. Wigginton, R. Fenton, Jong-Wook Park, 2001, The Journal of Immunology.

Mammary Epithelial Apoptosis Expression , Infiltration , Fas / Fas Ligand Gene IL-12 / Pulse IL-2 : Induction of Local T Cell Programmed Neoplastic Transition by Therapeutic Prevention of Genetically Spontaneous Mammary Carcinoma and the Complete Regression of Established

J. Ward, R. Strieter, J. Wigginton, 2000 .

Recruitment of hepatic NK cells by IL-12 is dependent on IFN-gamma and VCAM-1 and is rapidly down-regulated by a mechanism involving T cells and expression of Fas.

J. Wigginton, J. Ortaldo, R. Wiltrout, 1998, Journal of immunology.

Lack of FasL-mediated killing leads to in vivo tumor promotion in mouse Lewis lung cancer

J. Wigginton, T. Sayers, T. Back, 2003, Apoptosis.

IFN-γ-Dependent Delay of In Vivo Tumor Progression by Fas Overexpression on Murine Renal Cancer Cells1 2

J. Wigginton, T. Sayers, A. Brooks, 2000, The Journal of Immunology.

Murine Renal Cancer Cells Progression by Fas Overexpression on-Dependent Delay of In Vivo Tumor

J. Wigginton, T. Sayers, A. Brooks, 1999 .

Interleukin 12 primes macrophages for nitric oxide production in vivo and restores depressed nitric oxide production by macrophages from tumor-bearing mice: implications for the antitumor activity of interleukin 12 and/or interleukin 2.

J. Wigginton, D. Kuhns, T. Back, 1996, Cancer research.

Evaluation of the Antitumor Activity of the Interleukin‐12/Pulse Interleukin‐2 Combination a

J. Franco, J. Green, J. Wigginton, 1996, Annals of the New York Academy of Sciences.

A phase I dose-escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) administered in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (Pts) with advanced refractory solid tumors.

J. Wolchok, B. Fox, F. Hodi, 2013 .

Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): Long-term patient follow-up.

David C. Smith, T. Choueiri, M. Atkins, 2013 .

Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

B. Fox, J. Dipersio, J. Wigginton, 2017 .

Safety and tolerability of vorinostat—Experience from the vorinostat clinical trial program

D. Siegel, J. Wigginton, C. Belani, 2008 .

Anti-PD-1 (BMS-936558/MDX-1106/ONO-4538) in Patients With Advanced Solid Tumors: Clinical Activity, Safety, and Molecular Markers

David C. Smith, J. Taube, F. Hodi, 2012 .

Interleukin‐12: Murine Models of a Potent Antitumor Agent a

J. Wigginton, L. Luistro, R. Wiltrout, 1996, Annals of the New York Academy of Sciences.

The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response

P. Ascierto, C. Drake, B. Fox, 2020, Journal for immunotherapy of cancer.

Defining the critical hurdles in cancer immunotherapy

Zhigang Tian, Sylvia Janetzki, Cedrik M Britten, 2011, Journal of Translational Medicine.

Pediatric pancreatoblastoma: histopathologic and cytogenetic characterization of tumor and derived cell line.

T. Ried, J. Wigginton, C. Thiele, 2005, Cancer genetics and cytogenetics.

Reversal of ferritin-mediated immunosuppression by levamisole: a rationale for its application to management of the acquired immune deficiency syndrome (AIDS).

J. Wigginton, 1995, Medical hypotheses.

Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary.

P. Meltzer, M. Ladanyi, E. Kleinerman, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.

David C. Smith, T. Choueiri, M. Atkins, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.

J. Lacy, S. Park, Y. Bang, 2020, The Lancet. Oncology.

Safety and activity of CLN-081 (TAS6417) in NSCLC with EGFR Exon 20 insertion mutations (Ins20).

M. Socinski, E. Smit, V. Lee, 2021, Journal of Clinical Oncology.

4-18-2017 The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31 st anniversary annual meeting Howard

M. Atkins, R. Herbst, L. Garrison, 2018 .

Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy

L. Miller, J. Kirkwood, J. Galon, 2017, Journal of Immunotherapy for Cancer.

The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st anniversary annual meeting

M. Atkins, R. Herbst, L. Garrison, 2017, Journal of Immunotherapy for Cancer.

Combination immunotherapy: a road map

J. Wolchok, F. Hodi, P. Ott, 2017, Journal of Immunotherapy for Cancer.

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

David C. Smith, J. Taube, M. Atkins, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Complete Regression of Established Spontaneous Mammary Carcinoma and the Therapeutic Prevention of Genetically Programmed Neoplastic Transition by IL-12/Pulse IL-2: Induction of Local T Cell Infiltration, Fas/Fas Ligand Gene Expression, and Mammary Epithelial Apoptosis1 2

J. Ward, R. Strieter, J. Wigginton, 2001, The Journal of Immunology.

High-Throughput Molecular and Histopathologic Profiling of Tumor Tissue in a Novel Transplantable Model of Murine Neuroblastoma: New Tools for Pediatric Drug Discovery

Jun S. Wei, J. Wigginton, R. Orentas, 2012, Cancer investigation.

Multicolor Fluorescence-Based Approaches for Imaging Cytokine-Induced Alterations in the Neovascularization, Growth, Metastasis, and Apoptosis of Murine Neuroblastoma Tumors

J. Wigginton, J. Stauffer, T. Back, 2006, Journal of immunotherapy.

Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538).

David C. Smith, M. Atkins, J. Sosman, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.

David C. Smith, J. Sosman, L. Sequist, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Use of Cytokine Knockout Mice in Cancer Research

J. Wigginton, R. Wiltrout, W. Murphy, 2003 .

The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma

Cheryl Jorcyk, Christine Couldrey, Masa-Aki Shibata, 2000, Oncogene.

Cell Responses + and CD8 CD40 and IL-2: Coordination of Dendritic Administration of Agonistic Antibodies to Synergistic Anti-Tumor Responses After

J. Wigginton, T. Sayers, T. Back, 2003 .

IFN-gamma-dependent delay of in vivo tumor progression by Fas overexpression on murine renal cancer cells.

J. Wigginton, T. Sayers, A. Brooks, 2000, Journal of immunology.

Immunotherapy of cancer by IL-12-based cytokine combinations

J. Weiss, J. Wigginton, R. Wiltrout, 2007, Expert opinion on biological therapy.

Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers

S. H. van der Burg, F. Marincola, A. Palucka, 2011, Clinical Cancer Research.

Therapeutic modulation of Akt activity and antitumor efficacy of interleukin-12 against orthotopic murine neuroblastoma.

K. Nagashima, S. Lockett, J. Wigginton, 2006, Journal of the National Cancer Institute.

Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced melanoma (MEL).

J. Sosman, F. Hodi, M. Sznol, 2012 .

PD-1/PD-L1 pathway as a target for cancer immunotherapy: Safety and clinical activity of BMS-936559, an anti-PD-L1 antibody, in patients with solid tumors.

P. Hwu, J. Wigginton, A. Gupta, 2012 .

Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with previously treated metastatic renal cell carcinoma (mRCC).

David C. Smith, T. Choueiri, M. Atkins, 2012 .

Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response.

David C. Smith, J. Taube, M. Atkins, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combinaison d'anticorps anti-kir et d'anticorps anti-pd-1 pour le traitement du cancer

J. Wigginton, A. Gupta, S. Y. Kim, 2013 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor

J. Wolchok, C. Pratilas, N. Rosen, 2013, Cancer Immunology Research.

Combined Administration of IL-18 and IL-2 byFas-Ligand-Dependent Tumor Eradication and γ and Induction of IFN-Endogenous Anti-Tumor Immune Response Synergistic Engagement of an Ineffective

W. Alvord, J. Wigginton, T. Back, 2002 .

A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers"

Yingdong Zhao, Holden Maecker, Sylvia Janetzki, 2008, Journal of Translational Medicine.

Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial.

David C. Smith, J. Taube, M. Atkins, 2013 .

Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific Dart® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

S. Rutella, J. Dipersio, J. Wigginton, 2018, Blood.

Systemic interferon‐γ therapy for cutaneous melanoma: Subversive role of keratinocyte prostaglandin E production induced by interferon‐γ

J. Wigginton, 1988 .

Phase I dose escalation study of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced hepatocellular carcinoma (HCC) with or without chronic viral hepatitis.

J. Prieto, B. Sangro, T. Crocenzi, 2013 .

IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy.

J. Wigginton, T. Back, R. Wiltrout, 2001, The Journal of clinical investigation.

The potential role of serum ferritin in the pathogenesis of acquired immune deficiency syndrome (AIDS).

J. Wigginton, 1989, Medical hypotheses.

Management of Cytokine Release Syndrome in AML Patients Treated with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Molecule for T-Cell Redirected Therapy

C. Viero, J. Dipersio, J. Wigginton, 2018, Blood.

Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 Immunotherapies

B. Fox, J. Dipersio, P. Moore, 2017 .

A phase I, first-in-human study of MGD006/S80880 (CD123 x CD3 DART) in AML/MDS.

J. Dipersio, J. Wigginton, G. Martinelli, 2017 .

Induction of transplantable mouse renal cell cancers by streptozotocin: in vivo growth, metastases, and angiogenic phenotype.

J. Ward, J. Wigginton, T. Back, 2001, Cancer research.

IL-27 Mediates Complete Regression of Orthotopic Primary and Metastatic Murine Neuroblastoma Tumors: Role for CD8+ T Cells1

R. Kastelein, J. Wigginton, J. Stauffer, 2004, The Journal of Immunology.

Primary hepatocytes from mice treated with IL-2/IL-12 produce T cell chemoattractant activity that is dependent on monokine induced by IFN-gamma (Mig) and chemokine responsive to gamma-2 (Crg-2).

J. Wigginton, R. Fenton, R. Wiltrout, 2001, Journal of immunology.

Genitourinary tumors, non-prostate

S. J. Park, I. Tannock, S. Groshen, 2012 .

Clinical activity and safety of antiprogrammed death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in patients (pts) with previously treated, metastatic renal cell carcinoma (mRCC): An updated analysis.

David C. Smith, T. Choueiri, M. Atkins, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab.

C. Horak, J. Wolchok, M. Sznol, 2013 .

A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART® Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia

J. Wigginton, A. Wei, J. Rowe, 2019, Blood.

A phase 1, open label, dose escalation study of MGD009, a humanized B7-H3 x CD3 DART protein, in combination with MGA012, an anti-PD-1 antibody, in patients with relapsed or refractory B7-H3-expressing tumors.

P. Moore, J. Wigginton, J. Strauss, 2018 .

The immunological impact of the RAF inhibitor BMS908662: Preclinical and early clinical experience in combination with CTLA-4 blockade.

J. Wolchok, M. Callahan, J. Wigginton, 2012 .

Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL).

C. Horak, J. Wolchok, M. Sznol, 2013 .

A phase I study of lirilumab (BMS-986015), an anti-KIR monoclonal antibody, administered in combination with ipilimumab, an anti-CTLA4 monoclonal antibody, in patients (Pts) with select advanced solid tumors.

F. Hodi, G. Gibney, N. Rizvi, 2013 .

Clinical Activity and Safety of Anti-Programmed Death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in Patients (PTS) with Previously Treated, Metastatic Renal Cell Carcinoma (MRCC)

David C. Smith, T. Choueiri, M. Atkins, 2012 .

Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response.

David C. Smith, J. Taube, M. Atkins, 2012 .

A phase I study of the safety, tolerability, pharmacokinetics, and immunoregulatory activity of urelumab (BMS-663513) in subjects with advanced and/or metastatic solid tumors and relapsed/refractory B-cell non-Hodgkin’s lymphoma (B-NHL).

H. Kohrt, J. Wolchok, F. Hodi, 2013 .

Phase 1, first-in-human, open label, dose escalation ctudy of MGD009, a humanized B7-H3 x CD3 dual-affinity re-targeting (DART) protein in patients with B7-H3-expressing neoplasms or B7-H3 expressing tumor vasculature.

A. Tolcher, P. Moore, J. Wigginton, 2016 .

A phase 1, open-label, dose escalation study of enoblituzumab (MGA271) in pediatric patients with B7-H3-expressing relapsed or refractory solid tumors.

J. Maris, P. Moore, J. Wigginton, 2017 .

Anti-Programmed Death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in Patients (PTS) with Advanced Solid Tumors: Clinical Activity, Safety, and Molecular Markers

David C. Smith, J. Taube, F. Hodi, 2012 .

Melanoma and other skin tumors

Y. S. Kim, Su Jin Lee, J. Utikal, 2012 .

Phase 1b/2 study of margetuximab (M) plus pembrolizumab (P) in advanced HER2+ gastroesophageal junction (GEJ) or gastric (G) adenocarcinoma (GEA).

S. Park, Y. Bang, Yoon-Koo Kang, 2018 .

Phase I dose escalation study of recombinant interleukin-21 (rIL-21; BMS-982470) in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced or metastatic solid tumors.

C. Drake, J. Wigginton, L. Chow, 2013 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor

J. Wolchok, C. Pratilas, N. Rosen, 2013, Cancer Immunology Research.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.

Flotetuzumab (FLZ), an Investigational CD123 x CD3 Bispecific Dart® Protein-Induced Clustering of CD3+ T Cells and CD123+ AML Cells in Bone Marrow Biopsies Is Associated with Response to Treatment in Primary Refractory AML Patients

B. Fox, J. Wigginton, C. Bifulco, 2019, Blood.